By RTT News, April 11, 2013, 10:33:00 AM EDT
(RTTNews.com) – Bristol-Myers Squibb (BMY) announced Thursday that it plans to invest about $250 million to expand its large-scale biologics manufacturing facility in Devens, Massachusetts. The company said that the expansion will introduce biologics development and clinical trial manufacturing capabilities to the site, while adding about 350 employees to the Devens workforce over time.
The company noted that it plans to construct two new buildings on its 89-acre Devens campus. One will be dedicated to Process Development, a group that designs processes for early production of investigational biologics medicines. A second building will house Clinical Manufacturing, where investigational medicines will be produced to support clinical trials. Both represent new capabilities for Devens, a site that in its early years has focused solely on large-scale, bulk biologics manufacturing.